A Phase 1/2 interventional study of Carfilzomib and Dexamethasone in Multiple Myeloma, sponsored by Amgen. Completed at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-23.
Sponsored by Amgen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.
Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 25th largest by enrollment, is one of 11 that started in 2012, is one of 28 in phase 1/2, and was the 30th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Australia, Brazil and 5 more countries
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 78 · Phase 3 15 · Phase 4 2
First in 2005; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 54 across the 113 interventional studies. Of the 67 that completed or were terminated, 46 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 113 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
43 studies in Multiple Myeloma by Amgen: none open now, none under way, none of them phase 3. Of 41 finished, 36 (88%) have results posted.
Among the 43 studies in Multiple Myeloma by Amgen, this one is the 17th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2012, is one of 6 in phase 1/2, and was the 20th registered.
Amgen’s Multiple Myeloma studies by the year they started, since 2005.
18 of the studies testing carfilzomib in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT04096066Phase 3Fondazione EMN Italy OnlusA Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | 2027-09-01 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 113 studies testing carfilzomib in Multiple Myeloma, from their registry updates:
Among Amgen’s 43 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study had the following primary objectives:
This is a Phase 1/2, multicenter, single-arm, nonrandomized, open-label and dose-escalation study of weekly carfilzomib and dexamethasone for patients with progressive multiple myeloma. The Phase 1 dose escalation portion will enroll patients into sequential dose-escalating cohorts consisting of 3 patients each to establish the maximum tolerated dose (MTD) of carfilzomib administered weekly as a 30 minute intravenous (IV) infusion with dexamethasone. The Phase 2 portion will enroll patients using the MTD established for carfilzomib from the Phase 1 portion of the study. Dexamethasone will be administered IV or orally at the same dose and schedule as used in the Phase 1 portion of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
, as defined by 1 or more of the following (assessed within 21 days prior to enrollment):
Exclusion Criteria:
Second within the past 3 years, except:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In phase 1 participants were assigned to one of four sequential dose-escalating cohorts to receive 45, 56, 70 or 88 mg/m² carfilzomib administered by intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle. Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15. In phase 2 participants received carfilzomib at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study on days 1, 8 and 15 plus 40 mg dexamethasone IV or orally at the same schedule as used in the Phase 1 portion of the study. Participants were treated until confirmed progressive disease, unacceptable toxicity, withdrew consent for further treatment, were lost to follow-up, died, or the sponsor closed the study.
Drug: Carfilzomib · Drug: Dexamethasone
Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.
Also known as: Krypolis
Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.
Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)
The MTD was defined as the highest carfilzomib dose at which \< 33% of participants had a treatment-related DLT during the first 28-day cycle. A DLT was categorized as nonhematologic or hematologic and defined as follows: Nonhematologic: * ≥ grade 3 nonhematological toxicity (excluding nausea, vomiting, diarrhea, fatigue lasting \< 14 days, increased serum creatinine or electrolyte abnormalities not clinically significant or requiring treatment) * ≥ grade 3 acute kidney injury (creatinine \> 3 x baseline or \> 4.0 mg/dL) lasting \> 72 hours * ≥ grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal antiemetic/antidiarrheal therapy Hematologic: * grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 500/mm³) for \> 7 days * febrile neutropenia (ANC \< 1000/mm³ with a fever ≥ 38.3ºC) of any duration * grade 4 thrombocytopenia (\< 25 000/mm³) for \> 14 days, despite holding treatment * grade 3 or 4 thrombocytopenia (\< lower limit of normal) associated with \> grade 1 bleeding
Time frame: 28 days
Overall Response Rate (ORR)
Disease response was evaluated by the investigator according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). ORR was defined as the percentage of participants with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM. VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein \<100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.
Time frame: Disease response was assessed once every treatment cycle (28 days) and 30 days after last dose; the median overall treatment duration was 33.6 weeks.
Clinical Benefit Response Rate
Clinical benefit rate was defined as the percentage of participants whose best response was sCR, CR, VGPR, PR, or minimal response (MR), where MR is defined by the European Group for Blood and Marrow Transplant (EBMT) criteria as a 25% to 49% reduction in the level of serum M-protein or a 50% to 89% reduction in 24-hour urinary M-protein, which still exceeds 200 mg /24 hour, maintained for a minimum of 8 weeks.
Time frame: Disease response was assessed once every treatment cycle (28 days) and 30 days after last dose; the median overall treatment duration was 33.6 weeks.
Progression-free Survival
Progression-free survival (PFS) was defined as the time from first dose to the earlier of disease progression or death due to any cause. The duration of PFS was calculated using Kaplan-Meier methods; participants with no baseline and/or post-baseline disease assessments, who started a new anticancer therapy before documentation of disease progression or death, died or had disease progression immediately after more than 1 consecutively missed disease assessment visit or who were alive without documentation of disease progression before the data cutoff date were censored. Participants were evaluated for disease response and progression by the investigator according to the IMWG-URC.
Time frame: From randomization until the data cut-off date of 22 July 2016; median follow-up time for PFS was 13.8 months
Time To Progression
Time to progression (TTP) was defined as the time from first dose to disease progression evaluated by the investigator according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). TTP was calculated using Kaplan-Meier methods; participants with no baseline and/or post-baseline disease assessments, who started a new anticancer therapy before documentation of disease progression or death, died or had disease progression immediately after more than 1 consecutively missed disease assessment visit or who were alive without documentation of disease progression before the data cutoff date were censored.
Time frame: From randomization until the data cut-off date of 22 July 2016; median follow-up time for TTP was 13.4 months
Duration of Response
Duration of response (DOR) was defined as the time from first evidence of PR or better to disease progression or death due to any cause. DOR was calculated using Kaplan-Meier methods; Participants with no baseline disease assessments, starting a new anticancer therapy before documentation of disease progression or death, death or disease progression immediately after more than 1 consecutively missed disease assessment visit, or alive without documentation of disease progression before the data cut-off date were censored.
Time frame: From randomization until the data cut-off date of 22 July 2016; median follow-up time for DOR was 14.3 months
Number of Participants With Adverse Events
Adverse events were graded using National Cancer Institute-Common Terminology Criteria for Adverse Events (version 4.03).
Time frame: From the first day of study treatment and within 30 days of the last day of study treatment; median duration of treatment was 33.6 weeks.
Time to Maximum Plasma Concentration of Carfilzomib
Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Maximum Plasma Concentration of Carfilzomib
Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Carfilzomib
Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) fo Carfilzomib
Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Area Under the Plasma Concentration-time Curve During the Dosing Interval (0-168 Hours) for Carfilzomib
Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Volume of Distribution Observed at Steady State (Vss) for Carfilzomib
Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Terminal Half-life (T1/2,z) for Carfilzomib
Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Clearance of Carfilzomib After IV Infusion
Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
Mean Residence Time Observed From Time Zero to Infinity (MRT0-∞) for Carfilzomib
Time frame: Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.
This study was conducted at 32 centers in the United States. Participants were enrolled from September 2012 to September 2014.
| Milestone | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² |
|---|---|---|---|---|---|
| Started | 3 | 3 | 15 | 6 | 89 |
| Completed | 0 | 1 | 1 | 0 | 4 |
| Not completed | 3 | 2 | 14 | 6 | 85 |
| Withdrew: Adverse event | 0 | 0 | 2 | 3 | 13 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 2 | 0 | 12 |
| Withdrew: Progressive disease | 2 | 1 | 9 | 3 | 43 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 | 15 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
The MTD was defined as the highest carfilzomib dose at which \< 33% of participants had a treatment-related DLT during the first 28-day cycle. A DLT was categorized as nonhematologic or hematologic and defined as follows: Nonhematologic: * ≥ grade 3 nonhematological toxicity (excluding nausea, vomiting, diarrhea, fatigue lasting \< 14 days, increased serum creatinine or electrolyte abnormalities not clinically significant or requiring treatment) * ≥ grade 3 acute kidney injury (creatinine \> 3 x baseline or \> 4.0 mg/dL) lasting \> 72 hours * ≥ grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal antiemetic/antidiarrheal therapy Hematologic: * grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 500/mm³) for \> 7 days * febrile neutropenia (ANC \< 1000/mm³ with a fever ≥ 38.3ºC) of any duration * grade 4 thrombocytopenia (\< 25 000/mm³) for \> 14 days, despite holding treatment * grade 3 or 4 thrombocytopenia (\< lower limit of normal) associated with \> grade 1 bleeding
| participants | Phase 1 Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² |
|---|---|---|---|---|
| Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) | 0 | 0 | 1 | 2 |
Disease response was evaluated by the investigator according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). ORR was defined as the percentage of participants with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM. VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein \<100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.
| percentage of participants | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² | Phase 1+2: Carfilzomib 70 mg/m² |
|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 33.3 (0.8 to 90.6) | 100 (29.2 to 100.0) | 93.3 (68.1 to 99.8) | 66.7 (22.3 to 95.7) | 74.2 (63.8 to 82.9) | 76.9 (67.6 to 84.6) |
Clinical benefit rate was defined as the percentage of participants whose best response was sCR, CR, VGPR, PR, or minimal response (MR), where MR is defined by the European Group for Blood and Marrow Transplant (EBMT) criteria as a 25% to 49% reduction in the level of serum M-protein or a 50% to 89% reduction in 24-hour urinary M-protein, which still exceeds 200 mg /24 hour, maintained for a minimum of 8 weeks.
| percentage of participants | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² | Phase 1+2: Carfilzomib 70 mg/m² |
|---|---|---|---|---|---|---|
| Clinical Benefit Response Rate | 66.7 (9.4 to 99.2) | 100.0 (29.2 to 100.0) | 100.0 (78.2 to 100.0) | 83.3 (35.9 to 99.6) | 80.9 (71.2 to 88.5) | 83.7 (75.1 to 90.2) |
Progression-free survival (PFS) was defined as the time from first dose to the earlier of disease progression or death due to any cause. The duration of PFS was calculated using Kaplan-Meier methods; participants with no baseline and/or post-baseline disease assessments, who started a new anticancer therapy before documentation of disease progression or death, died or had disease progression immediately after more than 1 consecutively missed disease assessment visit or who were alive without documentation of disease progression before the data cutoff date were censored. Participants were evaluated for disease response and progression by the investigator according to the IMWG-URC.
| months | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² | Phase 1+2: Carfilzomib 70 mg/m² |
|---|---|---|---|---|---|---|
| Progression-free Survival | 13.6 (6.4 to 20.7) | NA (41.7 to NA) | 21.0 (4.2 to NA) | 12.9 (3.9 to 20.0) | 15.3 (10.0 to 20.2) | 16.2 (10.2 to 21.0) |
Time to progression (TTP) was defined as the time from first dose to disease progression evaluated by the investigator according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). TTP was calculated using Kaplan-Meier methods; participants with no baseline and/or post-baseline disease assessments, who started a new anticancer therapy before documentation of disease progression or death, died or had disease progression immediately after more than 1 consecutively missed disease assessment visit or who were alive without documentation of disease progression before the data cutoff date were censored.
| months | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² | Phase 1+2: Carfilzomib 70 mg/m² |
|---|---|---|---|---|---|---|
| Time To Progression | 13.6 (6.4 to 20.7) | NA (41.7 to NA) | 21.0 (4.2 to NA) | 12.9 (3.9 to 20.0) | 16.2 (10.2 to 20.2) | 17.2 (10.6 to 21.7) |
Duration of response (DOR) was defined as the time from first evidence of PR or better to disease progression or death due to any cause. DOR was calculated using Kaplan-Meier methods; Participants with no baseline disease assessments, starting a new anticancer therapy before documentation of disease progression or death, death or disease progression immediately after more than 1 consecutively missed disease assessment visit, or alive without documentation of disease progression before the data cut-off date were censored.
| months | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² | Phase 1+2: Carfilzomib 70 mg/m² |
|---|---|---|---|---|---|---|
| Duration of Response | 18.9 (NA to NA) | NA (39.9 to NA) | 16.3 (3.3 to NA) | 11.9 (11.1 to 18.9) | 18.0 (13.7 to 21.9) | 18.0 (14.5 to 21.9) |
Adverse events were graded using National Cancer Institute-Common Terminology Criteria for Adverse Events (version 4.03).
| Participants | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² |
|---|---|---|---|---|---|
| All adverse events | 3 | 3 | 15 | 6 | 89 |
| Adverse events ≥ grade 3 | 1 | 2 | 9 | 5 | 60 |
| Serious adverse events | 1 | 0 | 4 | 1 | 35 |
| AE leading to discontinuation of carfilzomib & dex | 0 | 0 | 2 | 3 | 14 |
| AE leading to discontinuation of carfilzomib | 0 | 0 | 2 | 3 | 14 |
| Fatal adverse events | 0 | 0 | 0 | 0 | 5 |
| hours | Carfilzomib 20 mg/m² | Carfilzomib 70 mg/m² | Carfilzomib 88 mg/m² |
|---|---|---|---|
| Time to Maximum Plasma Concentration of Carfilzomib | 0.25 (0.17 to 0.75) | 0.25 (0.08 to 0.58) | 0.25 (0.25 to 0.58) |
| ng/mL | Carfilzomib 20 mg/m² | Carfilzomib 70 mg/m² | Carfilzomib 88 mg/m² |
|---|---|---|---|
| Maximum Plasma Concentration of Carfilzomib | 789 ± 65.5 | 2390 ± 30.7 | 3090 ± 27.3 |
| hr*ng/mL | Carfilzomib 20 mg/m² | Carfilzomib 70 mg/m² | Carfilzomib 88 mg/m² |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Carfilzomib | 281 ± 52.7 | 1040 ± 21.7 | 1210 ± 31.4 |
| hr*ng/mL | Carfilzomib 20 mg/m² | Carfilzomib 70 mg/m² | Carfilzomib 88 mg/m² |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) fo Carfilzomib | 259 ± 28.0 | 1040 ± 21.6 | 1160 ± 34.8 |
| hr*ng/mL | Carfilzomib 20 mg/m² | Carfilzomib 70 mg/m² | Carfilzomib 88 mg/m² |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve During the Dosing Interval (0-168 Hours) for Carfilzomib | 259 ± 28.0 | 1040 ± 21.6 | 1160 ± 34.8 |
| liters | Carfilzomib 20 mg/m² | Carfilzomib 70 mg/m² | Carfilzomib 88 mg/m² |
|---|---|---|---|
| Volume of Distribution Observed at Steady State (Vss) for Carfilzomib | 17.0 ± 133.3 | 14.2 ± 54.2 | 7.87 ± 78.4 |
| hours | Carfilzomib 20 mg/m² | Carfilzomib 70 mg/m² | Carfilzomib 88 mg/m² |
|---|---|---|---|
| Terminal Half-life (T1/2,z) for Carfilzomib | 0.648 ± 49 | 0.883 ± 24.6 | 0.816 ± 17.1 |
| liters/hour | Carfilzomib 20 mg/m² | Carfilzomib 70 mg/m² | Carfilzomib 88 mg/m² |
|---|---|---|---|
| Clearance of Carfilzomib After IV Infusion | 147 ± 31.0 | 131 ± 29.6 | 138 ± 35.0 |
| hours | Carfilzomib 20 mg/m² | Carfilzomib 70 mg/m² | Carfilzomib 88 mg/m² |
|---|---|---|---|
| Mean Residence Time Observed From Time Zero to Infinity (MRT0-∞) for Carfilzomib | 0.118 ± 130.5 | 0.108 ± 55.4 | 0.0571 ± 110.0 |
Collected over From the first day of study treatment and within 30 days of the last day of study treatment; median duration of treatment was 33.6 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Carfilzomib 45 mg/m² | — | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1: Carfilzomib 56 mg/m² | — | 0/3 (0%) | 3/3 (100%) |
| Phase 1: Carfilzomib 70 mg/m² | — | 4/15 (26.7%) | 15/15 (100%) |
| Phase 1: Carfilzomib 88 mg/m² | — | 1/6 (16.7%) | 6/6 (100%) |
| Phase 2: Carfilzomib 70 mg/m² | — | 35/89 (39.3%) | 87/89 (97.8%) |
| Event | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² |
|---|---|---|---|---|---|
| Blood creatinine increasedInvestigations | 1/3 | 0/3 | 0/15 | 0/6 | 0/89 |
| HyponatraemiaMetabolism and nutrition disorders | 1/3 | 0/3 | 0/15 | 0/6 | 0/89 |
| Cardiac failure congestiveCardiac disorders | 0/3 | 0/3 | 0/15 | 1/6 | 2/89 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 2/15 | 0/6 | 3/89 |
| Acute kidney injuryRenal and urinary disorders | 0/3 | 0/3 | 1/15 | 0/6 | 6/89 |
| PneumoniaInfections and infestations | 0/3 | 0/3 | 1/15 | 0/6 | 4/89 |
| SepsisInfections and infestations | 0/3 | 0/3 | 1/15 | 0/6 | 5/89 |
| Urinary tract infectionInfections and infestations | 0/3 | 0/3 | 1/15 | 0/6 | 1/89 |
| EncephalopathyNervous system disorders | 0/3 | 0/3 | 1/15 | 0/6 | 0/89 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/15 | 0/6 | 2/89 |
| Event | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² |
|---|---|---|---|---|---|
| FatigueGeneral disorders | 3/3 | 2/3 | 9/15 | 3/6 | 47/89 |
| Upper respiratory tract infectionInfections and infestations | 1/3 | 2/3 | 12/15 | 2/6 | 25/89 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 2/3 | 5/15 | 1/6 | 25/89 |
| Vision blurredEye disorders | 0/3 | 2/3 | 1/15 | 2/6 | 5/89 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 0/3 | 9/15 | 2/6 | 26/89 |
| Cardiac murmurInvestigations | 0/3 | 2/3 | 0/15 | 0/6 | 2/89 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 2/3 | 5/15 | 0/6 | 15/89 |
| Back painMusculoskeletal and connective tissue disorders | 2/3 | 0/3 | 5/15 | 1/6 | 18/89 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/3 | 2/3 | 0/15 | 0/6 | 0/89 |
| HeadacheNervous system disorders | 0/3 | 2/3 | 6/15 | 4/6 | 26/89 |
| Age, Continuous(years) | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² | Total |
|---|---|---|---|---|---|---|
| Mean | 69.3 ± 15.6 | 73.7 ± 2.1 | 62.4 ± 10.4 | 58.2 ± 8.8 | 68.7 ± 9.6 | 67.5 ± 10.1 |
| Sex: Female, Male(Participants) | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 2 | 4 | 5 | 40 | 52 |
| Male | 2 | 1 | 11 | 1 | 49 | 64 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 10 | 11 |
| Not Hispanic or Latino | 3 | 3 | 15 | 5 | 79 | 105 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² | Total |
|---|---|---|---|---|---|---|
| White | 3 | 2 | 11 | 6 | 79 | 101 |
| Black or African American | 0 | 1 | 2 | 0 | 6 | 9 |
| Asian | 0 | 0 | 0 | 0 | 1 | 1 |
| American Indian or Alaskan Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 1 |
| Other | 0 | 0 | 2 | 0 | 1 | 3 |
| Unknown | 0 | 0 | 0 | 0 | 1 | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Phase 1: Carfilzomib 45 mg/m² | Phase 1: Carfilzomib 56 mg/m² | Phase 1: Carfilzomib 70 mg/m² | Phase 1: Carfilzomib 88 mg/m² | Phase 2: Carfilzomib 70 mg/m² | Total |
|---|---|---|---|---|---|---|
| 0 (Fully active) | 1 | 2 | 6 | 3 | 39 | 51 |
| 1 (Restrictive but ambulatory) | 2 | 1 | 9 | 3 | 50 | 65 |
The record gives a start of Jul 2012, a primary completion of Jul 2016 and a completion of Oct 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carfilzomib